TII
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Cryptography Research Centre (CRC) has launched the first Post-Quantum Cryptography (PQC) software library in the UAE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005486/en/
The library will advance the cryptographic and security capabilities of the emirate of Abu Dhabi and the broader UAE. International and Emirati researchers at Cryptography Research Centre, one of Technology Innovation Institute’s initial seven dedicated research centres, have developed the PQC library, a software library written in the C general-purpose programming language that supports a wide variety of computer architectures and operating systems. A corresponding hardware FPGA-based implementation has also been developed. The library, designed to guard against attacks by quantum computers, has been already integrated in several secure communication products.
The library is a collection of algorithms to safeguard confidential data and information. With the rise of quantum computers, classic cryptographic algorithms (in particular, public key / asymmetric algorithms) are no longer sufficient to ensure secure data storage and secure digital communication. To address the demand for an advanced level of security that cannot be compromised even on sophisticated quantum computers, cryptographers are now engaged in developing PQC algorithms.
Cryptography Research Centre employs and collaborates with scientists in multiple cryptography fields such as post-quantum cryptography, hardware-based cryptography, lightweight cryptography, cryptanalysis, cryptographic protocols, and cloud encryption schemes, amongst others. The Centre is also among the few internationally that brings together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes.
Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC), said: “The United Arab Emirates is now in the same league of countries that possess advanced digital data security capabilities. Our researchers have worked hard to make this revolutionary project a reality. To meet the growing level of sophistication in the world of data, systems and network security, we are currently engaged in many more such ventures for the future. Our researchers are shaping the building blocks of advanced cryptographic and cryptanalytic solutions that enable superior data confidentiality, integrity, authentication, non-repudiation, and privacy.”
Dr Najwa Aaraj, Chief Researcher at the Cryptography Research Centre, said: “Quantum computing capabilities are a potential threat to data security. This fact underscores the importance of the launch of the UAE’s first post-quantum cryptography library to guard against quantum computer attacks. The first release of the library has already been integrated in several secure communication products with advanced cryptographic protocols. Such a library serves as the foundation of any security application or product in development today that integrates public-key cryptography functionality. We will continue to develop the PQC library through incorporating more schemes.”
Technology Innovation Institute is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005486/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom